English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe invention of a tool capable of unlocking previously impossible organic chemical reactions has opened new pathways in the pharmaceutical industry to create effective drugs more quickly.
Tag: Pharmaceucticals
Exercise-mimicking drug sheds weight, boosts muscle activity in mice
A new drug encourages weight loss and increases endurance by making the body act like it is exercising.
Plasma electrochemistry offers novel way to form organic chemical bonds
Plasma engineers and chemists at the University of Illinois demonstrated a sustainable way of forming carbon-carbon bonds — the bedrock of all organic compounds — without expensive rare metals that are typically required as catalysts.
Different approach needed to ‘buy time’ and tackle COVID-19
A prominent Australian pharmacologist has called for a new approach to treating COVID-19 as hopes fade of finding an effective vaccine or antiviral before the end of the year.
Pharmacist clears up confusion about new COVID-19 drug
Remdesivir might shorten duration of symptoms in severely ill patients
‘Rushed’ Drug Development that Aims to Refill Pharma Firms’ Pipelines Is Less Likely to Succeed Because of Inter-organizational Friction
When a large pharmaceutical company experiences a drug trial failure and then tries to refill its pipeline by licensing a product created by another firm, such a “rushed innovation” is less likely to bring a product to market than one developed under normal, less hurried conditions. That’s because the hastily drawn licensing agreement between the two organizations leads to friction that drags development work to a halt.
Pharmacists separate COVID-19 fact from fiction
UGA medication experts answer common questions they’re receiving from patients
Rutgers Expert Available to Discuss How to Help Free Market Fight Coronavirus
New Brunswick, N.J. (March 25, 2020) – Stephen K. Burley, director of the RCSB Protein Data Bank headquartered at Rutgers University–New Brunswick, is available for interviews on how to help the free market fight the coronavirus. His viewpoint is published in the journal Nature. “Had drug…
Expert on #FDA’s #Expanded Access program: Cost can be a barrier to critically ill patients, healthcare providers, and others seeking to try experimental treatments as a last resort. Dr. Marjorie A. Speers available to comment or participate in inter
Costs related to the expanded access procedure under which critically ill patients can try experimental drugs, biologics, and medical devices are often overlooked. These costs, according to Clinical Research Pathways Executive Director Marjorie A. Speers, Ph.D. can become a barrier for patients,…